Danish Novo Nordisk is halving the price of the bestseller Ozempic on the American market. Patients can after the price reduction get the medicine for diabetes for 499 dollars per month.
In parallel, the price is also reduced by just as much on the weight loss agent Wegovy, which is based on the same pharmaceutical substance as Ozempic.
The management of Novo Nordisk says in the statement that the price reduction is not related to the US President Donald Trump's demand that the pharmaceutical giants must lower the price on the American market.
The share is rising sharply on the Copenhagen Stock Exchange, which is also related to the fact that the pharmaceutical company has received clearance from the American pharmaceutical authority for the treatment of liver disease.
